ABT-494 is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders, with potential for an improved safety profile compared with non-selective JAK inhibitors. This work characterized the pharmacokinetics, safety, and tolerability of ABT-494 following single and multiple dosing of the immediate-release formulation.
ABT-494 single (1–48 mg or placebo; n = 56) and multiple (3–24 mg or placebo twice daily for 14 days; n = 44) doses in healthy subjects, as well as multiple doses (3–24 mg or placebo twice daily for 27 days; n = 14) in subjects with rheumatoid arthritis (RA) on a background of methotrexate were evaluated. Pharmacokinetic samples were collected and safety and tolerability were assessed.
ABT-494 followed bi-exponential disposition, with a terminal elimination half-life of 6–16 h and a functional half-life, calculated from maximum observed plasma concentration (C max) to trough plasma concentration (C trough) ratio at steady state, of 3–4 h. ABT-494 exposure was approximately dose proportional over the 3–36 mg dose range, with no significant accumulation with repeated dosing. In subjects with RA, no pharmacokinetic interaction between ABT-494 and methotrexate was observed. The fraction of ABT-494 dose eliminated in urine as unchanged ABT-494 was 14–25 %. All treatment-emergent adverse events (TEAEs) were mild or moderate in severity, with headache being the most frequently observed TEAE (15.6 % for ABT-494 vs. 16.7 % for placebo) after multiple twice-daily administration to healthy subjects. No clinically significant changes in laboratory parameters, vital signs, or electrocardiogram findings in healthy or RA subjects were observed.
The favorable pharmacokinetics, safety, and tolerability results from these studies supported further evaluations of ABT-494 in phase IIb dose-ranging trials in RA and Crohn’s disease.
ClinicalTrials.gov (https://clinicaltrials.gov/) identifier: NCT01741493.
This is a preview of subscription content,to check access.
Access this article
Wilkie WS, Schwieterman P. Strategies for the management of rheumatoid arthritis. Orthopedics. 2012;35(2):125–30.
Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Phys. 2005;72(6):1037–47.
Leonard WJ. Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol. 2001;73(3):271–7.
O’Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542–50.
Vaddi K, Luchi M. JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy. Expert Opin Investig Drugs. 2012;21(7):961–73.
Isomaki P, Junttila I, Vidqvist KL, Korpela M, Silvennoinen O. The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels. Rheumatol (Oxf). 2015;54(6):1103–13.
He Y, Wong AY, Chan EW, Lau WC, Man KK, Chui CS, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2013;14:298.
Zerbini CA, Lomonte AB. Tofacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2012;8(4):319–31.
Kontzias A, Kotlyar A, Laurence A, Changelian P, O’Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol. 2012;12(4):464–70.
Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93(3):397–409.
Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014;23(8):1067–77.
Voss J, Graff C, Schwartz A, Hyland D, Argiriadi M, Camp H, et al. Pharmacodynamics of a novel Jak1 selective inhibitor in rat arthritis and anemia models and in healthy human subjects. Arthritis Rheum. 2013;65(10):1.
Kremer JM, Keystone EC, Emery P, Camp HS, Friedman A, Wang L, et al. Safety and efficacy of ABT-494, a novel selective JAK1 inhibitor, in patients with active rheumatoid arthritis and inadequate response or intolerance to anti-TNF biologic therapy. Arthritis Rheumatol. 2015;67(Suppl):10.
AbbVie. A study investigating the efficacy and safety of ABT-494 given with methotrexate (MTX) in subjects with rheumatoid arthritis who have had an inadequate response to MTX alone [ClinicalTrials.gov identifier NCT02066389]. US National Institutes of Health, ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov. Accessed 22 Apr 2016.
AbbVie. A multicenter, randomized, double-blind, placebo-controlled study of ABT-494 for the induction of symptomatic and endoscopic remission in subjects with moderately to severely active Crohn’s disease who have inadequately responded to or are intolerant to anti-TNF therapy (Celest Study) [ClinicalTrials.gov identifier NCT02365649]. US National Institutes of Health, ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov. Accessed 22 Apr 2016.
AbbVie. A study comparing ABT-494 to placebo and to adalimumab in subjects with rheumatoid arthritis who are on a stable dose of methotrexate and who have an inadequate response to methotrexate (SELECT-COMPARE) [ClinicalTrials.gov identifier NCT02629159]. US National Institutes of Health, ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov. Accessed 22 Apr 2016.
AbbVie. A study comparing ABT-494 monotherapy to methotrexate (MTX) monotherapy in subjects with rheumatoid arthritis (RA) who have an inadequate response to MTX (SELECT-MONOTHERAPY) [ClinicalTrials.gov identifier NCT02706951]. US National Institutes of Health, ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov. Accessed 22 Apr 2016.
AbbVie. A study to compare ABT-494 to placebo in subjects with rheumatoid arthritis on stable dose of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) who have an inadequate response or intolerance to biologic DMARDs (SELECT-BEYOND) [ClinicalTrials.gov identifier NCT02706847]. US National Institutes of Health, ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov. Accessed 22 Apr 2016.
AbbVie. A study in healthy adults and adult subjects with rheumatoid arthritis to evaluate the safety, tolerability and pharmacokinetics after multiple doses of ABT-494 [ClinicalTrials.gov identifier NCT01741493]. US National Institutes of Health, ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov. Accessed 22 Apr 2016.
Dutta S, Reed RC. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug: as shown by once-daily divalproex-ER. Clin Drug Investig. 2006;26(12):681–90.
FDA. Guidance for industry. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007. Available at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074775.htm.
Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res. 2008;25(12):2869–77.
FDA, Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): tofacitinib. Application number 203214Orig1s000. 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000ClinPharmR.pdf.
Namour F, Diderichsen PM, Cox E, Vayssiere B, Van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIb dose selection. Clin Pharmacokinet. 2015;54(8):859–74.
Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.
Ma MH, Kingsley GH, Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatol (Oxf). 2010;49(1):91–8.
Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–39.
Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.
Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004;50(9):2766–74.
This work was supported by AbbVie. AbbVie contributed to the study design, research, and interpretation of data, and reviewing and approving the publication. Drs. Mohamed, Camp, Padley, Asatryan and Othman, and Ms. Jiang are employees and shareholders of AbbVie.
About this article
Cite this article
Mohamed, ME.F., Camp, H.S., Jiang, P. et al. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. Clin Pharmacokinet 55, 1547–1558 (2016). https://doi.org/10.1007/s40262-016-0419-y